Cell Lines Characterization and Treatment

HH, H9, Hut78, MJ and Hut102 patient-derived CTCL cell lines were previously described [55 (link), 56 (link)] and were purchased from the American Tissue Culture Collection (ATCC). H9 is a clonal derivative of Hut78 cell line [57 (link)]. MyLa, PB2B, Mac2A, SZ4, SeAx, Sez4 were a generous gift from professors K. Kaltoft and N. Ødum (Copenhagen, Denmark) and were initially described elsewhere [31 (link), 58 (link)–61 (link)]. Detailed summary of cell lines is provided in Supplementary Table 1. MJ, Hut78 cells were serially passaged in IMDM media (Invitrogen) containing 20% and 10% fetal bovine serum, respectively (FBS) (Invitrogen). HH, H9, Hut102, MyLa, Mac2A and SZ4 cells were grown in RPMI media containing 10% FBS. Finally, Sez4 and SeAx cells were grown in RPMI media containing 10% FBS, 5 ng/mL of recombinant human IL-2 and IL-4 (R&D Systems, Minneapolis, MN). All cells were grown in 5% CO₂, 95% air humidified incubator at 37°C.
To inhibit histone deacetylase (HDAC) activity cells were treated with 0-40 μM of Suberoylanilide Hydroxamic Acid (SAHA also known as Vorinostat, Santa Cruz, Dallas, TX) or 0-4μM Romidepsin (Adooq Bioscience, Irvine CA). Cells were also treated with 0-40μM of Bexarotene (Santa Cruz Biotechnology, Dallas, TX).